Comparative Pharmacology
Head-to-head clinical analysis: ALEVE versus IBUPROHM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE versus IBUPROHM.
ALEVE vs IBUPROHM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
2-4 hours in adults; prolonged to 1.5-2.5 hours in neonates? Actually: terminal half-life ~2-4 h in adults, up to 12 h in overdose; context: requires frequent dosing.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Renal: 90% as metabolites (mostly glucuronide conjugates) and unchanged drug (1%); biliary/fecal: <5%.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)